Skip to main content

Table 1 BACE1 inhibitors in clinical trials

From: Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs

Drug MK-8931 JNJ-54861911 AZD-3293 E2609 CNP520
Sponsor Merck Janssen, Shionogi Pharma AstraZeneca, Eli Lilly Eisai, Biogen Novartis, Amgen
Trial # (Phase) NCT01739348 (II/III) NCT02406027 (II) NCT02245737 (II/III) NCT02322021 (II) NCT02576639 (II)
NCT01953601 (II/III) NCT02406027 (II) NCT02565511 (II/III)
NCT02569398 (II/III)
Dose 12, 40 or 60 mg 10, 25 or 50 mg 20 or 50 mg 25, 50, 100 and 200 mg 1, 10, 25 and 75 mg
Trial duration 78, 104 and 260 weeks 26, 52 or 96 weeks or 54 months 97 or 104 weeks 18 months 13 weeks and 5 years
1st Outcomes Baseline change in ADAS-Cog and ADCS-ADL scores Safety measure by AEs or SAEs up to 10 months; Baseline change in ADCS-PACC Score (54 weeks), Baseline change in CDR-SB Score Baseline change in ADCOMS, Safety measure by AEs or SAEs Safety measure by AEs or SAEs
2nd Outcomes Baseline change in CDR-SB score; CSF tau, brain amyloid load, NPI score, hippocampal volume, MMSE, score, etc. Baseline change in CSF and plasma Aβ37, Aβ38, Aβ40, Aβ42, sAPPα, sAPPβ, Tau; CFI; CDR-SB, Neurodegeneration by Assessing Changes in Imaging Biomarkers, etc. Baseline change in ADAS-Cog-13 score; CSF Aβ40, Aβ42, Tau; brain amyloid load by PET imaging, while brain volume, NPI score; ADCS-ADL score, etc. volumetric Magnetic Resonance Imaging; Baseline change in CSF and plasma Aβ1-x, etc. Baseline change in CDR-SB score; CSF Aβ40, Aβ42, total tau and phosphorylated tau, volumetric MRI; Everyday Cognition scale, etc.
  1. More detailed measures of outcomes are listed under each trail protocol in the relevant website
  2. Abbreviations used in the table: ADAS-Cog-13 Score Alzheimer’s disease assessment scale- cognitive subscale score, ADCOMS Alzheimer’s disease composite score, ADCS-ADL Alzheimer’s disease cooperative study activities of daily living inventory instrumental items score, ADCS-PACC Score Alzheimer’s disease cooperative study preclinical alzheimer cognitive composite score, CDR Score change in clinical Dementia rating global score, CDR-SB Score the clinical Dementia rating - sum of boxes score, CFI cognitive function index, FAQ Score functional activities questionnaire score, MMSE Score mini-mental state examination score, NPI Score neuropsychiatric inventory score, Safety and tolerability by assessing adverse events (AEs) and serious adverse events (SAEs)